





		EMLc	ATC codes: <span style="background-color: #00b050; color: white; padding: 2px;">J01DD04</span>
<b>Indication</b>	Other specified pneumonia	ICD11 code: <span style="background-color: #00728f; color: white; padding: 2px;">CA40.Y</span>	
<b>INN</b>	Ceftriaxone		
<b>Medicine type</b>	Chemical agent		
<b>Antibiotic groups</b>	<span style="border: 1px solid black; padding: 2px; display: inline-block;"> WATCH</span>		
<b>List type</b>	Core (EML) (EMLc)		
<b>Additional notes</b>	Do not administer with calcium and avoid in infants with hyperbilirubinaemia.		
<b>Formulations</b>	Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML)		
<b>EML status history</b>	First added in 2017 ( <span style="color: #00b050;">TRS 1006</span> ) Changed in 2021 ( <span style="color: #00b050;">TRS 1035</span> ) Changed in 2023 ( <span style="color: #00b050;">TRS 1049</span> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Age restriction</b>	> 41 weeks corrected gestational age		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <span style="color: #00b050;">about patents.</span> 		
<b>Wikipedia</b>	<span style="color: #00b050;">Ceftriaxone</span> 		
<b>DrugBank</b>	<span style="color: #00b050;">Ceftriaxone</span> 		

### Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

### EML recommendations: Other specified pneumonia

**First choice**

---

**Second choice**

---

## HOSPITAL-ACQUIRED PNEUMONIA

piperacillin + tazobactam

amoxicillin + clavulanic acid

cefotaxime

ceftriaxone

